Alzheimer’s Association Funds Gender-Based Research Efforts

Alzheimer’s Association pic

Alzheimer’s Association
Image: alz.org

Scott Robarge is an experienced recruitment professional with more than a decade of experience in the industry. In 2010, he founded Another8, a recruiting firm that specializes in partnering with early to mid-stage technology companies. Outside of his professional pursuits, Scott Robarge focuses his philanthropic efforts toward supporting the Alzheimer’s Association.

The Alzheimer’s Association recently announced $2.2 million in funding for its Sex and Gender in Alzheimer’s (SAGA) initiative that will be distributed to nine studies aimed at understanding why women are disproportionately affected by Alzheimer’s disease.

There are approximately 5 million Americans that suffer from Alzheimer’s, with more than two-thirds of that number being women. According to recent data gathered by the Alzheimer’s Association, in adults over the age of 71, there is a 16 percent rate of the disease, but only an 11 percent rate among men.

While there are some working theories as to why women suffer more than men from Alzheimer’s, researchers still have no definitive answers. The Alzheimer’s Association hopes that, through funding research projects, more knowledge about the gender disparity will be gained.

Advertisements

Antibodies New Wave of Alzheimer’s Research

Alzheimer's Research pic

Alzheimer’s Research
Image: sciencedaily.com

A seasoned recruiter and entrepreneur, Scott Robarge is the founder of Another8, a recruiting firm that primarily acquires talent for fast-paced technology companies. When he isn’t serving as a recruiter, Scott Robarge supports organizations that help lead the fight against Alzheimer’s disease.

Recent research efforts into the treatment of Alzheimer’s disease are focused on fighting the plaques that develop in the brain. Researchers believe that by understanding how to better manage these plaques, they may be able to delay its onset.

These plaques, which are a common sign of the condition, are tiny batches of beta-amyloid protein that deposit themselves in the brain and are responsible for brain cell degradation. Some antibodies, such as Aducanumab, have shown the propensity to reduce the amount of plaques that develop in Alzheimer’s patients, effectively slowing the rate of cognitive decline. It is thought that future research efforts in the battle against Alzheimer’s could include other combinations of medications in conjunction with these sorts of antibodies.